Issue 35, 2016, Issue in Progress

Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging

Abstract

The current strategies for drug/gene and multimodal imaging probes integrated into a single nanoparticle have some limitations still. Here, multifunctional chitosan hybrid nanoparticles (denoted as FA–CS–FITC(DOX/C-dots)/VEGF shRNA) containing folic acid (FA), fluorescein isothiocyanate (FITC) and doxorubicin (DOX)/carbon quantum dots (C-dots)/VEGF shRNA were fabricated as a targeted drug/gene co-delivery nanovector for potential cancer therapy and fluorescence imaging. The self-assembled FA–CS–FITC(DOX/C-dots)/VEGF shRNA nanocomplexes exhibited a desirable and homogenous particle size (154 ± 24 nm), moderate positive charges (23.2 ± 1.8 mV) and superior stability. The nanocomplexes without noteworthy cytotoxicity are capable of delivering VEGF shRNA into human cervical cancer HeLa cells with high efficiency while effectively protecting shRNA from degradation by exogenous DNase I and nucleases. The release behavior of DOX exhibited a biphasic pattern characterized by an initial burst release followed by a slower and continuous release at both pH 7.4 and pH 4.5, and also presented a pH-triggered release profile. Confocal microscopy analysis confirmed that both FA-targeted function and FA-enhanced buffering capacity induced high transfection, specific cellular uptake and efficient intracellular delivery of FA–CS–FITC(DOX/C-dots)/VEGF shRNA nanocomplexes in folate receptor-overexpressed HeLa cells. Transfected HeLa cells exhibited significantly decreased VEGF expression, inhibited cell proliferation, and increased cell apoptosis, which led to synergistic antitumor activities. Furthermore, the nanocomplexes demonstrated excellent dual fluorescence cellular imaging at a modest concentration. This work indicates that the integrated theranostic design of FA–CS–FITC(DOX/C-dots)/VEGF shRNA nanocomplexes potentially allows for the image-guided and target-specific treatment of cancer.

Graphical abstract: Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging

Supplementary files

Article information

Article type
Paper
Submitted
11 Feb 2016
Accepted
15 Mar 2016
First published
17 Mar 2016

RSC Adv., 2016,6, 29685-29696

Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging

H. Yang, M. Xu, S. Li, X. Shen, T. Li, J. Yan, C. Zhang, C. Wu, H. Zeng and Y. Liu, RSC Adv., 2016, 6, 29685 DOI: 10.1039/C6RA03843C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements